Fenofibric acid

SKU: orb1308727

Description

Fenofibric acid is the active metabolite of the antihyperlipidemic drug fenofibrate. It is widely used in research to study lipid metabolism, acting as a PPARα agonist in both in vitro and in vivo models of dyslipidemia and atherosclerosis.

Research Area

Immunology & Inflammation, Metabolism Research, Molecular Biology, Neuroscience, Protein Biochemistry

Key Properties

• CAS Number: 42017-89-0
• MW: 318.75
• Purity: 99.94%
• Formula: C₁₇H₁₅ClO₄
• SMILES: C(=O)(C1=CC=C(OC(C(O)=O)(C)C)C=C1)C2=CC=C(Cl)C=C2
• Target: MMP,PPAR,COX
• Solubility: 10% DMSO+40% PEG300+5% Tween 80+45% Saline:2 mg/mL (6.27 mM);DMSO:60 mg/mL (188.24 mM)

Bioactivity

• Target IC50:
  PPARα:22.4 µM(EC50)|PPARδ:1.06 µM(EC50)|COX-2:48 nM|PPARγ:1.47 µM(EC50)
• In Vivo:
  Fenofibric acid attenuates aberrant increases of circulating EPC(Endothelial Progenitor Cells) in OIR mice. Inhibitory effect of Fenofibric acid on EPC mobilization in the OIR model is PPARα-dependent.Fenofibric acid Inhibits hypoxia-induced retinal EPC increase in a PPARα-dependent manner. Fenofibric acid decreases CXCR4-positive EPC in the circulation, downregulates the serum SDF-1 level and suppresses HIF-1a and SDF-1 overexpression in the retina.
• In Vitro:
  Fibric acids, active forms of fibrate drugs and activators of peroxisome proliferator-activated receptor-alpha (PPARα), are also known for an HDL-raising effect. Fibric acids enhance fatty acid catabolism and accordingly reduce plasma lipid level, predominantly triglyceride (TG). Fenofibric acid increases the expression of ABCA1 and apoA-I–mediated HDL production. The effect on ABCA1 expression was through the enhancement of the transcription of the ABCA1 gene being dependent on LXR.
• Cell Research:
  PPAR activators fenofibric acid is dissolved in DMSO and added to the culture medium containing 0.2% BSA. RAW264 cells are washed with PBS and cultured an additional 48 hours in the presence of fenofibric acid in DMEM/F-12(1:1) medium containing 2% TCM and 0.2% BSA. During the last 24 hours of the drug treatment, 300 mol/L of dibutyryl cAMP and apoA-I (10 μg/mL) are added to the medium. THP-1 cells are also treated with the compound and apoA-I in 0.2% BSA-RPMI 1640 medium and 0.1% BSA-MEM. Cholesterol and choline-phospholipid released into the medium by apoA-I are determined enzymatically. Adherent cells are dissolved in 0.1 N NaOH for protein determination by bicinchoninic acid protein assay system. (Only for Reference)

Storage & Handling

• Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Cyclooxygenase, COX-2, COX, MMP, inhibit, Inhibitor, NSC281318, NSC-281318, NSC 281318, Fenofibric acid, FNF acid, Trilipix, PPARα, PPAR, Peroxisome proliferator-activated receptors

Compound Identifiers

PubChem CID

64929